Share on StockTwits

Stock Analysts’ ratings reiterations for Wednesday, August 13th:

Auxilium Pharmaceuticals (NASDAQ:AUXL) had its underperform rating reiterated by analysts at Zacks. The firm currently has a $16.00 price target on the stock. Zacks’ analyst wrote, “Auxilium’s second quarter results missed both revenues and earnings estimates primarily due to lower Testim revenues. Loss of $0.54 per share was much wider than the Zacks Consensus Estimate of a loss of $0.45 per share. Revenues decreased 17.4% year over year to $83.0 million in the second quarter and fell short of the Zacks Consensus Estimate of $91 million. While the Actient deal should help strengthen the company’s urology franchise and reduce its dependence on Testim, we are concerned about the lack of patent protection for some of the key Actient products. Auxilium is now treating Testim as a mature product and hence the company is banking heavily on the successful commercialization of Xiaflex and Stendra. We currently maintain our Underperform recommendation. . “

Coach (NYSE:COH) had its overweight rating reaffirmed by analysts at Piper Jaffray. The firm currently has a $29.00 price target on the stock, down from their previous price target of $32.00.

Cynapsus Therapeutic (NASDAQ:CYNAF) had its outperform rating reaffirmed by analysts at Zacks. The firm currently has a $2.25 price target on the stock. Zacks’ analyst wrote, “Little known Toronto, Canada-based Cynapsus Therapeutics is one of our best ideas for investment in the small-cap biotechnology sector. The company currently trades with a market capitalization of only $75 million, yet sits on a potential $750 million drug for the treatment of Parkinson’s disease. The leading drug is APL-130277, a sublingual formulation of apomorphine, designed as a rescue medication for patients experiencing “off” time in-between their daily levodopa dosing. We like Cynapsus because the costs and risks to develop APL-130277 are low, and the exit strategy is clear – develop APL-130277 to the point where a new drug application (NDA) can be filed, and then sell the company to a larger pharmaceutical looking to commercial. Based on the data and market research that we have seen, Cynapsus shares offer a potential six-fold increase in returns.”

Lloyds Banking Group PLC (NYSE:LYG) had its buy rating reiterated by analysts at Deutsche Bank.

MannKind (NASDAQ:MNKD) had its neutral rating reissued by analysts at Zacks. The firm currently has a $7.75 target price on the stock. Zacks’ analyst wrote, “MannKind’s second quarter 2014 net loss of $0.19 per share was wider than the year-ago loss of $0.16 and the Zacks Consensus Estimate of a loss of $0.11 We believe that the numbers put out by MannKind in the second quarter of 2014 are not as significant as the deal with Sanofi on Afrezza. We are positive on MannKind’s decision to choose a large company like Sanofi as a partner for Afrezza. Sanofi’s marketing muscle should go a long way in making the U.S. launch (expected in the first quarter of 2015) of Afrezza a success. The deal will result in a substantial inflow of cash at MannKind. We remain Neutral on the stock.”

MasTec (NYSE:MTZ) had its underperform rating reaffirmed by analysts at Zacks. The firm currently has a $26.00 price target on the stock. Zacks’ analyst wrote, “MasTec’s second-quarter 2014 adjusted earnings per share decreased 18% to $0.45 due to slowdown in revenue growth of wireless projects. For the third quarter, MasTec expects revenue of approximately $1.30-$1.35 billion and adjusted earnings per share of $0.56. For 2014, MasTec expects revenue of $4.4 to $4.5 billion and adjusted earnings within $1.55 to $1.58 per share. MasTec’s guidance reflects reduced levels of expected wireless project revenue in the second half of 2014, compared with the prior year. The company however anticipates returning to a more normalized level of wireless project revenue in 2015. We have maintained our Underperform recommendation on MasTec with a target price of $26.”

Prudential Public Limited Company (NYSE:PUK) had its overweight rating reaffirmed by analysts at Barclays.

Prudential Public Limited Company (NYSE:PUK) had its buy rating reaffirmed by analysts at Deutsche Bank.

Prudential Public Limited Company (NYSE:PUK) had its outperform rating reaffirmed by analysts at Credit Suisse.

Rio Tinto plc (NYSE:RIO) had its outperform rating reaffirmed by analysts at RBC Capital.

Sonoco Products Company (NYSE:SON) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $42.00 price target on the stock. Zacks’ analyst wrote, “We have maintained our Neutral recommendation on Sonoco Products with a target price of $42.00. Sonoco’s second-quarter 2014 adjusted earnings rose 74% y-o-y to $0.63 per share aided by improvements in productivity, favorable price/cost relationship, strong performances in Paper and Industrial Converted Products as well as Display and Packaging segments which offset higher input and operating costs and lower-than-expected results in Consumer Packaging and Protective Solutions segments. Sonoco will continue to benefit from the momentum in its Display and Packaging business, investments in new plants and product development center and recent price increase. However, weak volumes in the Consumer Packaging segment and soft spending environment remain concerns.”

Visa (NYSE:V) had its outperform rating reissued by analysts at Zacks. The firm currently has a $2.25 target price on the stock. Zacks’ analyst wrote, “Little known Toronto, Canada-based Cynapsus Therapeutics is one of our best ideas for investment in the small-cap biotechnology sector. The company currently trades with a market capitalization of only $75 million, yet sits on a potential $750 million drug for the treatment of Parkinson’s disease. The leading drug is APL-130277, a sublingual formulation of apomorphine, designed as a rescue medication for patients experiencing “off” time in-between their daily levodopa dosing. We like Cynapsus because the costs and risks to develop APL-130277 are low, and the exit strategy is clear – develop APL-130277 to the point where a new drug application (NDA) can be filed, and then sell the company to a larger pharmaceutical looking to commercial. Based on the data and market research that we have seen, Cynapsus shares offer a potential six-fold increase in returns.”

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.